# Audit Report: MHLW Pharmaceutical Affairs Deliberation (2026-01-12)

## üìÇ Data Provenance & Integrity (Source Evidence)
To ensure the auditability of the pharmaceutical data, the source document from Japan MHLW is anchored below.

- **Source Document:** MHLW Pharmaceutical Affairs Deliberation Committee Meeting (Japan)
- **Meeting Date:** January 12, 2026
- **Original File Name:** `20260112Rituxan.pdf`
- **SHA-256 Hash:** `106AEB33860660C551E821750EC05E0ACC30A0E00AC0D9330AF8C852DB14029F`
- **Source Link (JP MHLW):** [MHLW Meeting Minutes Jan 12, 2026](https://www.mhlw.go.jp/content/11121000/001629103.pdf)

---

## üîç Cross-Border Regulatory Comparison (Benchmarking)
This audit tracks the regulatory timeline differences between Japan (MHLW), the United States (FDA), and Taiwan (TFDA).

### üõ°Ô∏è Core Target: Rituximab (Rituxan)
**Case ID:** `2026-01-RITUXIMAB-CROSS-BORDER`

- **Japan MHLW Status:** Reported for partial dosage form changes (100mg/500mg IV) on Jan 12, 2026.
- **US FDA Evidence:** [FDA Label Update PDF (Jan 2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf)
- **Taiwan TFDA Status:** [Standard Drug Database Search](https://www.fda.gov.tw/TC/searchin.aspx) (Verified via TFDA portal)

---

## üìä Batch Audit Log (Index of Other Drugs)
Other significant drug actions discussed in the Jan 12, 2026 session:

| Drug Name (JP) | Generic Name | Developer | Indication | Audit Note |
| :--- | :--- | :--- | :--- | :--- |
| **Keens („Ç≠„Éº„É≥„Çπ)** | IcoSema | Novo Nordisk | Type 2 Diabetes | World's first once-weekly basal insulin combination. |
| **Sohonos („ÇΩ„Éõ„Éé„Çπ)** | Palovarotene | Ipsen | FOP (Stone Man Syndrome) | Tracking significant time gap (FDA approved in 2023). |
| **Aquipta („Ç¢„ÇØ„Ç§„Éó„Çø)** | Atogepant | AbbVie | Migraine Prevention | Deliberation on approval & re-examination extension. |

---

## üí° Audit Conclusion (Draft)
- **Observation:** The MHLW's deliberation on **Sohonos (Palovarotene)** in Jan 2026 highlights a significant administrative lag (~2.5 years) compared to the FDA approval in Aug 2023.
- **Objective:** OncoAudit v2.0.0 will continue to document these gaps to promote medical data transparency.

---
*This report is securely hashed and prepared for permanent storage on **Arweave/AO**.*
